Last Price$1.22NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$1.22 (39)
Ask (Size)$1.23 (1,901)
Day Low / HighN/A - N/A
Volume1.6 M

View Biotechnology IndustryPeer Comparison as of 08/12/2022


VBI Vaccines Inc ( NASDAQ )

Price: $1.22
Change: +0.12 (10.91%)
Volume: 1.6 M
4:00PM ET 8/12/2022

Cymabay Therapeutics Inc ( NASDAQ )

Price: $4.01
Change: +0.27 (7.22%)
Volume: 464.4 K
4:00PM ET 8/12/2022

Alaunos Therapeutics Inc ( NASDAQ )

Price: $1.65
Change: -0.13 (7.30%)
Volume: 1.8 M
4:00PM ET 8/12/2022

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.80
Change: +0.22 (2.56%)
Volume: 68.6 K
4:00PM ET 8/12/2022

Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.57
Change: +0.02 (1.29%)
Volume: 206.2 K
8:00PM ET 8/12/2022

Read more news Recent News

-- Earnings Flash (VBIV) VBI VACCINES Posts Q2 Revenue $346,000
8:01AM ET 8/08/2022 MT Newswires


VBI Vaccines Receives FDA Orphan Drug Designation for Glioblastoma Treatment
8:17AM ET 6/22/2022 MT Newswires

VBI Vaccines (VBIV) said Wednesday it has received orphan drug designation from the US Food and Drug Administration for VBI-1901, which is intended for the...

VBI Vaccines Says Vaccine Candidate for Brain Tumors Shows Survival Benefit in Expanded Trial Data
1:48PM ET 6/06/2022 MT Newswires

VBI Vaccines (VBIV) said Monday updated tumor response and overall survival data from a phase 2a trial of VBI-1901 cancer vaccine candidate for recurrent...

VBI Says UK Healthcare Regulator Grants Marketing Approval for Hepatitis B Vaccine
11:16AM ET 6/01/2022 MT Newswires

VBI Vaccines (VBIV) said Wednesday it has secured marketing approval by the UK Medicines and Healthcare Products Regulatory Agency for its hepatitis B...

Company Profile

Business DescriptionVBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA. View company web site for more details
Address160 2nd Street
Cambridge, Massachusetts 02142
Number of Employees112
President, Chief Executive Officer & DirectorJeff Baxter
CFO, Director & Head-Business DevelopmentChristopher McNulty
Chief Medical OfficerFrancisco Diaz-Mitoma
Chief Scientific OfficerDavid Evander Anderson

Company Highlights

Price Open$1.13
Previous Close$1.10
52 Week Range$0.64 - 3.81
Market Capitalization$315.1 M
Shares Outstanding258.3 M
SectorHealth Technology
Next Earnings Announcement11/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.39
Beta vs. S&P 500N/A
Revenue$3.4 M
Net Profit Margin-15,391.36%
Return on Equity-75.37%

Analyst Ratings as of 06/10/2021

Consensus RecommendationConsensus Icon
Powered by Factset